BrainCool’s CEO on the agreement with ZOLL
BrainCool has entered into a distribution agreement with US-based ZOLL, one of the world’s largest manufacturers and distributors of medical devices. The agreement covers the company’s IQool System for the treatment of neurological fever. BrainCool’s CEO Martin Waleij visited BioStock’s studio to talk about the deal, worth more than SEK 100 million.
Watch Martin Waleij present BrainCool and talk about the agreement with ZOLL below (in Swedish).
Read more about BrainCool här.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.